258 related articles for article (PubMed ID: 26954716)
1. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.
Green AR; Aleskandarany MA; Agarwal D; Elsheikh S; Nolan CC; Diez-Rodriguez M; Macmillan RD; Ball GR; Caldas C; Madhusudan S; Ellis IO; Rakha EA
Br J Cancer; 2016 Apr; 114(8):917-28. PubMed ID: 26954716
[TBL] [Abstract][Full Text] [Related]
2. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
El Ansari R; Craze ML; Miligy I; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res; 2018 Mar; 20(1):21. PubMed ID: 29566741
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
[TBL] [Abstract][Full Text] [Related]
4. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.
Agarwal R; Gonzalez-Angulo AM; Myhre S; Carey M; Lee JS; Overgaard J; Alsner J; Stemke-Hale K; Lluch A; Neve RM; Kuo WL; Sorlie T; Sahin A; Valero V; Keyomarsi K; Gray JW; Borresen-Dale AL; Mills GB; Hennessy BT
Clin Cancer Res; 2009 Jun; 15(11):3654-62. PubMed ID: 19470724
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Paish EC; Macmillan RD; Ellis IO; Green AR
Breast Cancer Res Treat; 2010 Jul; 122(1):45-53. PubMed ID: 19701705
[TBL] [Abstract][Full Text] [Related]
6. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
[TBL] [Abstract][Full Text] [Related]
8. MYC amplification in subtypes of breast cancers in African American women.
Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
10. The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer.
Habashy HO; Rakha EA; Ellis IO; Powe DG
Breast Cancer Res Treat; 2013 Jul; 140(2):307-16. PubMed ID: 23887673
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
12. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
13. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
14. The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
El Ansari R; Craze ML; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2018 Apr; 118(8):1115-1122. PubMed ID: 29545595
[TBL] [Abstract][Full Text] [Related]
15. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
16. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
Bozhanov SS; Angelova SG; Krasteva ME; Markov TL; Christova SL; Gavrilov IG; Georgieva EI
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1657-69. PubMed ID: 20177704
[TBL] [Abstract][Full Text] [Related]
17. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
Kurozumi S; Joseph C; Sonbul S; Gorringe KL; Pigera M; Aleskandarany MA; Diez-Rodriguez M; Nolan CC; Fujii T; Shirabe K; Kuwano H; Storr S; Martin SG; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2018 Aug; 170(3):525-533. PubMed ID: 29633055
[TBL] [Abstract][Full Text] [Related]
19. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
Craze ML; Cheung H; Jewa N; Coimbra NDM; Soria D; El-Ansari R; Aleskandarany MA; Wai Cheng K; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2018 Jan; 118(2):258-265. PubMed ID: 29169183
[TBL] [Abstract][Full Text] [Related]
20. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
El-Ansari R; Craze ML; Alfarsi L; Soria D; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 May; 175(1):27-38. PubMed ID: 30671766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
